BUZZ-Belgium's Agomab indicated to fall in Nasdaq debut after $200 million IPO

Reuters

Feb 07

** Belgium-based Agomab Therapeutics AGMB.O set to open below offer price in Nasdaq debut

** Stock indicated to open at $15.25 apiece versus $16 IPO price

** AGMB sold 12.5 million American Depositary Shares within marketed range of $15 to $17, to raise $200 million

** Founded in 2017, AGMB is developing treatments for immune and inflammatory diseases, starting with chronic fibrotic conditions

** AGMB's lead product candidate, ontunisertib, is being developed for fibrostenosing Crohn's disease, a severe form of Crohn's characterized by inflammation-driven structures that often lead to surgery

** J.P.Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen were joint book-running managers for the offering

(Reporting by Arasu Kannagi Basil in Bengaluru)

((ArasuKannagi.Basil@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609959024"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609959024\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609959024?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-07 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609959024","market":"nz","top_or_hot":-1,"title":"BUZZ-Belgium's Agomab indicated to fall in Nasdaq debut after $200 million IPO","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Belgium's Agomab indicated to fall in Nasdaq debut after $200 million IPO</title></head><body><p> ** Belgium-based Agomab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>AGMB.O</span> set to open below offer price in Nasdaq debut</p><p>** Stock indicated to open at $15.25 apiece versus $16 IPO price</p><p>** AGMB <span>sold</span> 12.5 million American Depositary Shares within <span>marketed range</span> of $15 to $17, to raise $200 million</p><p>** Founded in 2017, AGMB is developing treatments for immune and inflammatory diseases, starting with chronic fibrotic conditions</p><p>** AGMB's lead product candidate, ontunisertib, is being developed for fibrostenosing Crohn's disease, a severe form of Crohn's characterized by inflammation-driven structures that often lead to surgery</p><p>** J.P.Morgan, <a href=\"https://laohu8.com/S/MSPQL\">Morgan Stanley</a>, Leerink Partners and Van Lanschot Kempen were joint book-running managers for the offering</p><p>(Reporting by Arasu Kannagi Basil in Bengaluru)</p><p>((ArasuKannagi.Basil@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Belgium's Agomab indicated to fall in Nasdaq debut after $200 million IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Belgium's Agomab indicated to fall in Nasdaq debut after $200 million IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-07 00:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Belgium's Agomab indicated to fall in Nasdaq debut after $200 million IPO</title></head><body><p> ** Belgium-based Agomab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>AGMB.O</span> set to open below offer price in Nasdaq debut</p><p>** Stock indicated to open at $15.25 apiece versus $16 IPO price</p><p>** AGMB <span>sold</span> 12.5 million American Depositary Shares within <span>marketed range</span> of $15 to $17, to raise $200 million</p><p>** Founded in 2017, AGMB is developing treatments for immune and inflammatory diseases, starting with chronic fibrotic conditions</p><p>** AGMB's lead product candidate, ontunisertib, is being developed for fibrostenosing Crohn's disease, a severe form of Crohn's characterized by inflammation-driven structures that often lead to surgery</p><p>** J.P.Morgan, <a href=\"https://laohu8.com/S/MSPQL\">Morgan Stanley</a>, Leerink Partners and Van Lanschot Kempen were joint book-running managers for the offering</p><p>(Reporting by Arasu Kannagi Basil in Bengaluru)</p><p>((ArasuKannagi.Basil@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0820562030.AUD","symbol_name":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL4N3YZ1FY:1","article_id":"2609959024","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609959024","pubTimestamp":1770395760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Belgium's Agomab indicated to fall in Nasdaq debut after $200 million IPO ** Belgium-based Agomab Therapeutics AGMB.O set to open below offer price in Nasdaq debut** Stock indicated to open at $15.25 apiece versus $16 IPO price** AGMB sold 12.5 million American Depositary Shares within marketed range of $15 to $17, to raise $200 million** Founded in 2017, AGMB is developing treatments for immune and inflammatory diseases, starting with chronic fibrotic conditions** AGMB's lead product candidate, ontunisertib, is being developed for fibrostenosing Crohn's disease, a severe form of Crohn's characterized by inflammation-driven structures that often lead to surgery** J.P.Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen were joint book-running managers for the offering","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","BK4504":"桥水持仓","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","BK4588":"碎股","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","MNSH":"MNSN HLDGS INC.","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","BK4207":"综合性银行","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","AGMB":"AgomAb Therapeutics","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","SG9999002232.USD":"Allianz Global High Payout USD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","BK4516":"特朗普概念","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","BK4581":"高盛持仓","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BHPRN162.USD":"BNY MELLON BLOCKCHAIN INNOVATION \"B\" (USD) ACC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU0106831901.USD":"贝莱德世界金融基金A2","BK4585":"ETF&股票定投概念","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU2054465674.USD":"UBS (LUX) KEY SELEC SICAV DIGITAL TRANSFORMATION T \"P\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU2381873111.SGD":"BGF SYSTEMATIC GLOBAL EQUITY HIGH INCOME \"A6\" (SGDHDG) INC","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","IE00BYXW3230.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"AA\" (USD) ACC"},"translate_title":"BUZZ-Belgium的Agomab在IPO 2亿美元后表示在纳斯达克首次亮相将下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGMB":0.9,"MNSH":0.9},"content_text":"BUZZ-Belgium's Agomab indicated to fall in Nasdaq debut after $200 million IPO ** Belgium-based Agomab Therapeutics AGMB.O set to open below offer price in Nasdaq debut** Stock indicated to open at $15.25 apiece versus $16 IPO price** AGMB sold 12.5 million American Depositary Shares within marketed range of $15 to $17, to raise $200 million** Founded in 2017, AGMB is developing treatments for immune and inflammatory diseases, starting with chronic fibrotic conditions** AGMB's lead product candidate, ontunisertib, is being developed for fibrostenosing Crohn's disease, a severe form of Crohn's characterized by inflammation-driven structures that often lead to surgery** J.P.Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen were joint book-running managers for the offering(Reporting by Arasu Kannagi Basil in Bengaluru)((ArasuKannagi.Basil@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}